Pyrazole Compounds Modulating MAGL and FAAH Enzymes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions such as multiple sclerosis, Alzheimer's disease, inflammatory bowel disease, pain, and other disorders lack effective modulators or inhibitors for monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), enzymes involved in endocannabinoid metabolism, which are crucial for therapeutic benefits.
Innovation Solution
Development of compounds, such as those represented by Formulas (I), (II), and (III), which act as modulators or inhibitors of MAGL and/or FAAH, capable of inhibiting these enzymes to treat various diseases by regulating endocannabinoid levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for conditions such as multiple sclerosis, Alzheimer's disease, and pain, then existing therapeutic options are available, but effective modulators or inhibitors for MAGL and FAAH enzymes are lacking
Solution Approach 1:
The patent segments the therapeutic approach by developing separate but related compounds that selectively target different enzymes (MAGL and FAAH). Formula (I) compounds target MAGL while Formula (II) compounds target FAAH, allowing tailored treatment strategies for different conditions based on which enzyme modulation is most beneficial.
Solution Approach 2:
The patent creates a universal platform of pyrazole-based compounds that can function as either MAGL inhibitors or FAAH inhibitors depending on the specific molecular structure. The core pyrazole scaffold in both Formula (I) and Formula (II) provides a universal mechanism for enzyme inhibition, while substituent variations enable selective targeting of different enzymes within the same therapeutic platform.
2Reliability
If MAGL and FAAH enzymes are not inhibited, then endocannabinoid metabolism proceeds normally, but therapeutic benefits for conditions like multiple sclerosis and Alzheimer's disease are not achieved
Solution Approach 1:
The patent applies preliminary anti-action by designing compounds that preemptively inhibit MAGL and FAAH enzymes before endocannabinoid degradation occurs. By blocking these enzymes with Formula (I) or Formula (II) compounds, the therapeutic approach prevents the breakdown of endocannabinoids, thereby maintaining elevated levels of these neurotransmitters to treat conditions such as multiple sclerosis, Alzheimer's disease, and pain.
3Measurement precision
If compounds of Formula (I) and Formula (II) are developed, then specific enzyme inhibition is achieved, but complexity of compound structure increases
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at defined positions on the pyrazole scaffold to achieve enzyme selectivity. Formula (I) compounds have specific substituents (R1-R6) that optimize MAGL binding, while Formula (II) compounds have different substituents (R1-R6 plus R7-R8) that optimize FAAH binding. This localized modification of the core structure enables precise enzyme targeting without requiring complete structural redesign.
Solution Approach 2:
The patent employs composite molecular structures combining a core pyrazole scaffold with various functional groups and substituents. The composite nature of Formula (I) and Formula (II) compounds integrates the essential pyrazole core with additional moieties (such as aryl, alkyl, and heterocyclic groups) that collectively provide both structural stability and enzyme-specific recognition, achieving high selectivity through composite design rather than simple structures.
Data Source
AI summary
Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or FAAH. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain.